We hypothesized that chronic inflammatory process(es) underlie the pathophysiology of intractable epilepsy presenting with frequent seizures in children. We considered that daily frequent motor seizures may cause more inflammation than do less frequent seizures. Thus, we investigated inflammatory markers, including hs-CRP, PTX3, tumor necrosis factor (TNF)-a, interleukin (IL)-6, and IL-b1, in the blood of patients with daily frequent seizures, particularly generalized motor seizures, compared with those with less frequent seizures and control subjects.
Materials and methods

Patients and controls
From June 2013 to February 2014, 29 patients with epilepsy (14 boys, 15 girls) and 15 children (7 boys, 8 girls) as control subjects were enrolled. The control group consisted of patients from Hiroshima University Hospital without epilepsy, fever, acute illness, or any other immune-mediated disorders. Epilepsy patients were diagnosed based on medical history and electroclinical (seizure semiology and EEG/video-EEG) and neuroimaging findings. They were divided into two groups: those who had daily generalized motor seizures (epileptic spasms, tonic seizures, secondarily generalized tonic-clonic seizures, and myoclonic seizures) and those who had intermittent (less than daily) seizures.
Patients in the daily seizure (DS) group (n = 12; 7 boys, 5 girls) had more than three seizures/day and those in the intermittent seizures (IS) group (n = 17; 7 boys, 10 girls) had less than one seizure/ month. All patients in the DS group were monitored using a videoelectroencephalogram (EEG) monitoring system for more than 24 h, and their seizure types and frequencies were confirmed by epilepsy specialists with clinical information. Video-EEG monitoring was performed using 21 scalp electrodes, which were placed according to the international ''1-20'' system, with electromyogram (EMG) sensors placed on the bilateral deltoid muscles.
The mean ages of the children in the DS, IS, and control groups were 4.54 AE 3.00, 6.44 AE 3.41, and 5.49 AE 4.37 years, respectively. No statistically significant differences in age, gender, body mass index, or treatment duration were observed among the three groups (Table 1 , all p > 0.05). No patient in the DS or IS group had undergone any immune-related treatments, such as adrenocorticotropic hormone (ACTH), glucocorticoid, or immunoglobulin therapies, for at least 6 months before blood sampling.
This study was approved by the Hiroshima University Institutional Review Board. Written informed consent was obtained from the parents of each child.
2.2. Determination of serum hs-CRP, plasma PTX3, serum TNF-a, IL-6, and IL-1b levels Serum and plasma samples were collected from the children who had no symptoms of infectious or inflammatory diseases. Peripheral venous blood was withdrawn from each subject and centrifuged (2000 Â g, 20 min); serum or plasma was then isolated and stored at À80 8C for analysis within 6 h after collection. hs-CRP, PTX3, TNF-a, IL-6, and IL-1b concentrations were determined using commercially available kits. Hs-CRP concentrations were measured using a nephelometry method (N-Latex CRP II, Siemens Healthcare Diagnostics, Erlangen, Germany). PTX3 and TNF-a concentrations were each determined using quantitative sandwich enzyme immunoassay methods (Pentraxin 3 Quantikine for PTX3 and Quanti Glo Human TNF-a Chemiluminescent Immunoassay 2nd generation for TNF-a; R&D Systems, Minneapolis, MN, USA). IL-6 and IL-1b concentrations were measured by fluorescent beadbased immunoassays (Novex Singleplex Luminex Assay, Life Technologies, Carlsbad, CA, USA) based on the Luminex system (Luminex, Austin, TX, USA). All analyses were performed according to the manufacturers' instructions.
Statistical analyses
Data are shown as means AE standard deviation (SD), unless stated otherwise. Statistical analyses were performed using the statistical package 'R' (ver. 3.2.2; available at http://www.r-project.org). Numerical variables were compared using the Mann-Whitney U-test. A p value <0.05 was considered to indicate statistical significance. To examine differences between independent groups, the Kruskal-Wallis test and Fisher's exact test were used for categorical outcomes.
Results (Fig. 1)
Hs-CRP levels were significantly higher in the DS group (0.149 AE 0.161 mg/dL) than the IS and control groups (0.0156 AE 0.0136 and 0.0253 AE 0.0288 mg/dL; p < 0.005 and <0.05, respectively), whereas there was no significant difference between the IS and control groups. IL-6 levels were also significantly higher in the DS group (8.022 AE 0.161 pg/mL) than either the IS or control group (7.783 AE 0.0563 and 7.864 AE 0.072 pg/mL; p < 0.005 and < 0.05, respectively). The number of antiepileptic drugs (AEDs) used was significantly higher in the DS than IS group (2.583 vs. 1.471; p < 0.001). The PTX3 level was 0.72 AE 0.482 ng/mL in the DS group, 0.774 AE 0.463 ng/mL in the IS group, and 0.993 AE 0.539 ng/mL in the control group. Although the PTX3 level tended to be higher in the control group, no statistically significant difference was detected among the three groups. The TNF-a level was 1.245 AE 1.049 pg/mL in the DS group, 0.672 AE 0.537 pg/mL in the IS group, and 1.267 AE 1.084 pg/mL in the control group. The TNF-a level also tended to be higher in the control group, but no statistically significant difference was detected among the groups. The IL-1b level was 15.663 AE 0.0654 pg/mL in the DS group, 15.628 AE 0.037 pg/ mL in the IS group, and 15.634 AE 0.0331 pg/mL in the control group. There were no statistically significant differences among the groups.
Discussion
Experimental evidence indicates significant roles for inflammatory and immune mediators in the initiation of seizures and epileptogenesis. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In particular, cytokines including IL-1b, IL-6, and TNF-a, and Toll-like receptor 4 have been shown to contribute to seizure generation and epileptogenesis. 28, 29 In addition to experimental studies using animal models, human clinical studies have demonstrated alterations in the levels of IL-6 in samples from patients with epilepsy. 16 However, there are few data regarding TNF-a in patients with epilepsy, although seizures can induce the expression of TNF-a mRNA in the brains of animal models. 29 Experimental seizures were associated with post-ictal increases in IL-1b in the CNS, while no observable differences in IL-1b concentrations after seizure were demonstrated. 16, 20, 30 Our results were similar to these previous findings. A rapid and transient postictal increase was seen in IL-6, which peaked at 12 h and remained elevated at 24 h. 16, 17, 20 The reason a significant increase in IL-6 was observed in the DS group may be because the multiple generalized motor seizures each day sustained the production of IL-6 before its degradation/turnover. CRP, a member of the short pentraxins, is an established inflammatory marker produced by hepatocytes in response to inflammatory cytokines, such as IL-1, IL-6, and TNF-a, or to other stimulations. 10, 31 Measurement of hs-CRP levels has recently been recognized as a method to detect chronic inflammation in patients with cardiovascular diseases, 1,2,32 stroke, 7 renal disease, 33 and neurodegeneration diseases. 5, 34 PTX3 is a member of the long pentraxins produced in peripheral tissues and monocytic phagocytes in response to IL-1, TNF-a, and Toll-like receptor ligands. 35 In this study, we showed that hs-CRP levels in patients with daily generalized motor seizures were significantly higher than those in other epilepsy patients or control subjects. These results may indicate that frequent motor seizures can cause chronic inflammation. Alapirtti et al 22 . suggested that secondarily generalized tonic-clonic seizures stimulated CRP even though other partial seizures did not. Peltola et al. 21 reported a significant correlation between plasma IL-6 and CRP concentrations in patients with recent tonic-clonic seizures. Our results suggest that daily generalized motor seizures provoked elevation of IL-6, leading to increased CRP levels. Previous reports have shown that PTX3 is synthesized in the brain after seizures and may exert a protective role against seizureinduced neurodegeneration. 23 However, while plasma PTX3 has also been recognized as a biomarker of cardiovascular, renal disease, and systemic autoimmune diseases, 11, [36] [37] [38] [39] there is little information about its role as a plasma biomarker in patients with epilepsy. Although plasma PTX3 is useful for detecting vascular inflammation, 40 it may not be sensitive enough to provide inflammation about neuronal cells. We found no significant difference in PTX3 levels among the three groups. These results suggested that daily generalized motor seizures did not raise plasma PTX3 levels; however, there may be PTX3 production within the central nervous system. It has been reported that AEDs may affect inflammatory markers. One study that examined markers for atherosclerosis risk in 195 epilepsy patients treated with AEDs showed higher CRP levels compared with controls. 41 Valproate is associated with lower CRP. 42 Significantly lower CRP values have been shown to associate with the use of lamotrigine and levetiracetam, and a trend for higher CRP values has been reported for patients on phenytoin and carbamazepine. 43 Long-term use of AEDs generally may result in low-grade systemic inflammation and increased oxidative stress. 41 In this study, there was no significant difference in treatment duration between the DS and IS groups. The number of AEDs used in the DS group was significantly greater than that in the IS group due to the refractory clinical course of the DS group.
Yuen et al. 42 demonstrated no significant relationship between the number of AEDs taken and CRP. Thus, the higher levels of CRP in the DS group may be attributable to the frequent daily generalized motor seizures. This study has certain limitations. Although the participants presented with no obvious inflammatory symptoms, CRP concentrations may fluctuate slightly over time with unnoticeable, subtle conditions, which may affect the validity of CRP levels.
Librizzi et al. 44 reported that seizures initiate brain inflammation in glia and promote blood-brain barrier damage independently of leukocytes or blood-borne inflammatory molecules, and brain inflammation can contribute to the duration and recurrence of seizures. In this study, we did not evaluate the intracellular conditions of neuronal cells. Systemic inflammatory responses in the intractable patients may have affected their prognoses. The impact of systemic inflammatory responses on generalized motor seizures in pediatric patients with epilepsy needs to be evaluated. The possible utility of anti-epileptic and anti-epileptogenesis therapies that target inflammation has been reported. 27, 45 To treat intractable epilepsy, we may have to consider therapeutic strategies, including ways to control the inflammatory process too.
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